RS 0139
Alternative Names: RS-0139Latest Information Update: 15 Oct 2024
At a glance
- Originator RS Arastirma Egitim Danismanlik Ilac Sanayi Ticaret A.S.
- Class Antineoplastics; Drug conjugates; Polymers; Small molecules
- Mechanism of Action Integrin modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Phase I Non-small cell lung cancer
- Preclinical Head and neck cancer; Ovarian cancer; Prostate cancer
- No development reported Breast cancer
Most Recent Events
- 15 Oct 2024 RS 0139 is still in phase I trials for Non-small cell lung cancer in Turkey (PDC Therapeutics pipeline, October 2024)
- 28 Jun 2024 No recent reports of development identified for phase-I development in Non-small-cell-lung-cancer(Late-stage disease, Metastatic disease, Recurrent, Second-line therapy or greater) in Turkey
- 28 Mar 2024 No recent reports of development identified for preclinical development in Breast-cancer in Turkey